首页> 美国卫生研究院文献>Scientific Reports >Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2− subtype breast cancer
【2h】

Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2− subtype breast cancer

机译:较长的非编码RNA00544可作为HR + HER2-亚型乳腺癌的潜在新型预测和预后标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Luminal breast cancers (BC) account for majority of breast cancer. Due to its heterogeneity and the development of treatment resistance, luminal BC patients can vary substantially. Long noncoding RNAs (lncRNAs), as we known, is involved in breast cancer progression. Here, we aim to identify the lncRNAs which are involved in the particular type luminal BC progression. By Gene Chips analysis, we found a novel lncRNA00544, which was highly expressed in the metastatic axillary nodes compared with corresponding luminal BC tissues (fold change = 2.26, P = 0.043). This result was confirmed in luminal BC cell lines (p = 0.0113) and 49 paired breast cancer samples compared with in corresponding controls (p = 0.011). Furthermore, Kaplan–Meier survival curves of 373 breast cancer patients indicated that disease-free survival was significantly poor in breast cancer patients with high lncRNA00544 expression (p < 0.001). Univariate and multivariate Cox regression analyses showed that lncRNA00544 was a significant independent prognostic biomarker in luminal BC patients. Further analysis showed that the prognosis of high lncRNA00544 expression in breast cancer patients was actually related to HR + HER2− subtype. Together, our studies indicate that lncRNA00544 may represent a novel predictive and prognostic indicator in luminal BC patients.
机译:发光性乳腺癌(BC)占乳腺癌的大多数。由于其异质性和对治疗的抵抗力的发展,管腔BC患者可能会有很大差异。众所周知,长非编码RNA(lncRNA)参与了乳腺癌的发展。在这里,我们旨在鉴定参与特定类型的腔BC进程的lncRNA。通过基因芯片分析,我们发现了一种新型lncRNA00544,与相应的管腔BC组织相比,它在转移性腋窝淋巴结中高表达(倍数变化= 2.26,P = 0.043)。与相应对照相比,在管腔BC细胞系(p = 0.0113)和49个配对的乳腺癌样品中证实了这一结果。此外,对373名乳腺癌患者的Kaplan–Meier生存曲线表明,在具有高lncRNA00544表达的乳腺癌患者中,无病生存率显着降低(p <0.001)。单因素和多因素Cox回归分析显示lncRNA00544是管腔BC患者的重要独立预后生物标志物。进一步的分析表明,乳腺癌患者中lncRNA00544高表达的预后实际上与HR + HER2-亚型有关。总之,我们的研究表明,lncRNA00544可能代表管腔BC患者的新型预测和预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号